Tenderwize
Retour à la recherche

Accord de remise pour le fluorouracile

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline May 27, 2027 · 187 days left·Open·Supplies·Framework
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Fluorouracil (ATC-Code: D11AF05).

52/100

Score d'opportunité

Needs reviewHigh complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

69 / 100

Facteurs de risque

No value, volume, demand commitment or guaranteed spend is stated, so the commercial return cannot be assessed from the...

Open-house contracts may end automatically when exclusive rebate contracts enter into force, and the notice indicates t...

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Niedersachsen. Die Gesundheitskasse.
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
May 27, 2027

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Conclusion of non-exclusive rebate agreements for Fluorouracil medicines classified under ATC code D11AF05.
  • Open-house participation by eligible pharmaceutical companies under uniform contract contents, conditions and access procedures.
Afficher le résumé complet

AOK Niedersachsen offers a non-exclusive open-house rebate agreement for medicines containing Fluorouracil (ATC D11AF05) in Germany. Eligible pharmaceutical companies may join without a competitive selection decision under uniform, non-negotiable conditions. Contracts may start monthly during the maximum 24-month period, but can end automatically if exclusive rebate contracts enter into force. The initial 1 August 2025 accession deadline has passed; later access is stated to remain possible during the term, subject to the contractual submission deadlines. No contract value or procurement documents were provided for analysis.

Risques

No value, volume, demand commitment or guaranteed spend is stated, so the commercial return cannot be assessed from the...

Open-house contracts may end automatically when exclusive rebate contracts enter into force, and the notice indicates t...

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Participation is limited to pharmaceutical entrepreneurs within the meaning of Section 4(18) AMG, or a consortium of pharmaceutical entrepreneurs, in relation to the offered...
  • The pharmaceutical entrepreneur must have its registered seat in Germany, another EU Member State, or another EEA contracting state, as stated with reference to Section 9(2) AMG.
  • A local representative may participate only if it is itself a pharmaceutical entrepreneur for the relevant medicines.

Critères d'attribution

Lot 1

Price is identified as the award criterion; no description or numeric weighting is provided. In the open-house model, there is no stated competitive selection decision.

Acheteur

Localisation

Hannover, DEU

Identifiant

AOK- Niedersachsen. Die Gesundheitskasse

Activité

Health

Lots (1)

LOT-0000

Fluorouracil Non-Exclusive Rebate Agreement

Non-exclusive open-house rebate agreement under Section 130a(8) SGB V for medicines containing Fluorouracil (ATC D11AF05). All interested eligible pharmaceutical companies may join under identical conditions, without an award selection. Contracts may run for up to 24 months and end no later than 31 July 2027. The lot information is derived from the structured notice and TED XML notice.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE929, Germany

Durée

Jul 2025 - Jul 2027

Catégorie

Pharmaceutical products

Critères d'attribution

Price

Date limite

Deadline May 27, 2027

Détails de la procédure

Date de publication
12 Jun 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
381285-2025

Appels d'offres similaires

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy